jp morgan glp 1 After a big year for GLP-1s, the biopharma market is shifting. Chris Schott offers his 2026 outlook ahead of the 44th annual J.P. Healthcare Conference. The Next Wave in Obesity

The sustained effects of a dual GIP/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2

Author: Noelia Rivera-Gonzlez, MS, RD, LDN, CDCES | CCS Health This site is for educational purposes only

Individuals with Gastrointestinal Disorders : Conditions such as Crohns disease, celiac disease, and other digestive disorders can impair B12 absorption

L-carnitine is a compounded prescription medication and is not approved by the FDA

With significant results of GLP-1 receptor agonists in clinical trials , such as weight loss (up to 20%) and improved glycemic control, making them a preference for both physicians and patients

Safety & Contraindications GLOW and its component peptides are not FDA-approved drugs